<DOC>
	<DOCNO>NCT00276471</DOCNO>
	<brief_summary>Metacure MC PT TAN2005-013 feasibility study prospective , multi-center , study evaluate safety functionality TANTALUS System , treatment obese T2DM patient , assess effect GCT ( Glycemic Control Treatment ) weight loss glycemic control .</brief_summary>
	<brief_title>Evaluation Tantalus System Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<criteria>T2DM subject inadequately control maximum three oral agent Subjects HbA1c 7 9 % Subjects FBG 120 200 mg/dL Subjects 2160 year old Women childbearing potential ( i.e . postmenopausal surgically sterilize ) must agree use adequate birth control method must agree conceive least 20 week Subjects Body Mass Index ( BMI ) 3038 ( inclusive ) Subjects waist circumference &gt; 94 cm ( male ) &gt; 80 cm ( female ) Subjects stable medication program least three month oral medication program Subjects compliant , willing able participate followup visit study duration approximately 26 week Alert , mentally competent , able understand comply requirement clinical trial , personally motivate abide requirement restriction clinical trial . Able provide voluntary inform consent . Subjects high risk general anesthesia surgery Subjects prior pancreatitis Subjects chronic hepatitis Subjects elevate serum creatinine Subjects proliferative diabetic retinopathy Subjects gastroparesis intestinal pseudoobstruction Subjects motility disorder GI tract Subjects receiving medication know affect gastric motility Subjects past present psychiatric condition may impair ability comply study procedure Subjects pregnant ( proven positive hCG ) , lactate Subjects prior bariatric surgery Subjects history peptic ulcer disease Subjects use another investigational device agent 30 day prior implant participate clinical study Subjects new medical problem diagnose worsen exist medical problem baseline evaluation period Subjects lifethreatening comorbidity life expectancy le one year Subjects myocardial infarction one episodes unstable angina within 6 month prior enrollment Subjects history malignant disease Subjects currently chemotherapy treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>